The objective of the study was to evaluate the feasibility of implementing personalized medication services into community pharmacy practice and to assess the number of drug therapy problems identified as a result of pharmacogenomic screening.
The study was carried out in two community pharmacies in Toronto, Canada
One hundred patients taking a mean of 4.9 chronic medications were enrolled in the study. Pharmacists cited the most common reasons for pharmacogenomic (PGx) testing as ineffective therapy (43.0%), to address an adverse reaction (32.6%), and to guide initiation of therapy (10.4%). An average of 1.3 drug therapy problems directly related to the PGx testing were identified per patient. Pharmacist recommendations included change in therapy (60.3%), dose adjustment (13.2%), discontinuation of a drug (4.4%), and increased monitoring (22.1%).
Current status: The results of the study have been published in Journal of the American Pharmacists Association 57 (2017) 624-629